1. Home
  2. CVAC vs DXPE Comparison

CVAC vs DXPE Comparison

Compare CVAC & DXPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVAC
  • DXPE
  • Stock Information
  • Founded
  • CVAC 2000
  • DXPE 1908
  • Country
  • CVAC Germany
  • DXPE United States
  • Employees
  • CVAC N/A
  • DXPE N/A
  • Industry
  • CVAC Biotechnology: Pharmaceutical Preparations
  • DXPE Industrial Machinery/Components
  • Sector
  • CVAC Health Care
  • DXPE Industrials
  • Exchange
  • CVAC Nasdaq
  • DXPE Nasdaq
  • Market Cap
  • CVAC 1.2B
  • DXPE 1.4B
  • IPO Year
  • CVAC 2020
  • DXPE 1996
  • Fundamental
  • Price
  • CVAC $5.48
  • DXPE $118.76
  • Analyst Decision
  • CVAC Hold
  • DXPE Buy
  • Analyst Count
  • CVAC 3
  • DXPE 1
  • Target Price
  • CVAC $6.83
  • DXPE $95.00
  • AVG Volume (30 Days)
  • CVAC 789.9K
  • DXPE 231.0K
  • Earning Date
  • CVAC 08-18-2025
  • DXPE 08-06-2025
  • Dividend Yield
  • CVAC N/A
  • DXPE N/A
  • EPS Growth
  • CVAC N/A
  • DXPE 47.94
  • EPS
  • CVAC 0.87
  • DXPE 5.24
  • Revenue
  • CVAC $566,039,775.00
  • DXPE $1,919,100,000.00
  • Revenue This Year
  • CVAC N/A
  • DXPE $11.87
  • Revenue Next Year
  • CVAC $24.04
  • DXPE $3.57
  • P/E Ratio
  • CVAC $6.35
  • DXPE $22.68
  • Revenue Growth
  • CVAC 787.60
  • DXPE 13.93
  • 52 Week Low
  • CVAC $2.37
  • DXPE $45.81
  • 52 Week High
  • CVAC $5.72
  • DXPE $123.63
  • Technical
  • Relative Strength Index (RSI)
  • CVAC 60.60
  • DXPE 64.89
  • Support Level
  • CVAC $5.41
  • DXPE $101.02
  • Resistance Level
  • CVAC $5.54
  • DXPE $123.63
  • Average True Range (ATR)
  • CVAC 0.05
  • DXPE 5.15
  • MACD
  • CVAC -0.01
  • DXPE 0.33
  • Stochastic Oscillator
  • CVAC 73.68
  • DXPE 78.46

About CVAC CureVac N.V.

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

About DXPE DXP Enterprises Inc.

DXP Enterprises Inc is a distributor of products and services to industrial customers in the United States, Canada, Mexico, and Dubai. The company's reportable segments include Service Centers, Innovative Pumping Solutions, and Supply Chain Services. It generates maximum revenue from the Service Centers segment. The company offers pumping solutions, supply chain services and maintenance, repair, operating, and production services for rotating equipment, bearings, power transmissions, industrial supplies, and safety products. It serves the General Industrial, Oil & Gas, Food & Beverage, Water & Wastewater, Chemical, Transportation, Aerospace & Others.

Share on Social Networks: